Halozyme Therapeutics (HALO) Capital Leases (2012 - 2013)
Halozyme Therapeutics (HALO) posted quarterly Capital Leases of $2.6 million for Q3 2013, up 21.43% quarter-over-quarter from $2.1 million in Q2 2013.
Halozyme Therapeutics (HALO) Capital Leases (2012 - 2013) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Capital Leases for 2 consecutive years, with $2.6 million the latest figure, recorded in Q3 2013.
- In Q3 2013, Capital Leases changed N/A year-over-year to $2.6 million; the TTM figure through Sep 2013 stood at $2.6 million (changed N/A YoY), while the FY2012 annual figure was $1.4 million, changed N/A from the prior year.
- Capital Leases grew to $2.6 million in Q3 2013 per HALO's latest filing, from $2.1 million in the prior quarter.
- Across five years, Capital Leases topped out at $2.6 million in Q3 2013 and bottomed at $1.4 million in Q4 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2013 | 2.55 Mn |
| Jun 30, 2013 | 2.10 Mn |
| Mar 31, 2013 | 1.45 Mn |
| Dec 31, 2012 | 1.45 Mn |